Specifically, Lac16 pretreatment ameliorates colitis through microbiota-dependent mechanisms, including preservation of intestinal barrier integrity, attenuation of inflammatory responses, regulation of macrophage polarization, modulation of NLRP3 inflammasome activation, restoration of microbial homeostasis, and enhancement of beneficial SCFA production. Here, NLRP3 is linked to colitis.